Elizabeth Parrish (Matthias Arnold/picture-alliance/dpa/AP Images)
June 28, 2021 09:19 AM EDTUpdated July 2, 11:42 AM
R&D
Discovery

Con­tro­ver­sial an­ti-ag­ing sci­en­tist — backed by Har­vard's George Church — makes a fresh round of claims on life ex­ten­sion in new mouse study

John Carroll

Editor & Founder

Jason Mast

Editor

Just weeks ago con­tro­ver­sial an­ti-ag­ing re­searcher Eliz­a­beth Par­rish at­tract­ed con­sid­er­able at­ten­tion for a tiny hu­man gene ther­a­py study she claimed was …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times